Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncocort dose-escalation study in metastatic castration-resistant prostate cancer
NL-OMON45330Phase 1Active, not recruiting
- Sponsor
- Enceladus Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peg-liposomal dexamethasone sodium phosphate in prostate cancer (PCa), sponsored by Enceladus Pharmaceuticals. Primary endpoints: Safety and tolerability, Pharmacokinetics of liposomal and free dexamethasone and 8 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
peg-liposomal dexamethasone sodium phosphate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45330.